FDA expands Pluvicto label, making it available to most metastatic prostate cancer patients
RegulatoryapprovedPluvictoPositive
AI Analysis
Summary
The FDA approved Novartis' Pluvicto radiopharma drug for use alongside hormone therapy in metastatic prostate cancer, nearly doubling the eligible patient population. This label expansion significantly increases the drug's commercial potential by making it available to a broader patient base.
Outcome Details
FDA approved Pluvicto for use alongside hormone therapy, expanding label to nearly double the eligible patient population
Importance:8/10
Sentiment:
0.80
FDA approvallabel expansionradiopharmaceuticalprostate cancermarket access
Related Companies
Read the original article
Published by Endpoints News on August 3, 2026 3:26 PM